Italy: A new study published in Pediatric Research has questioned the long-standing practice of fluid restriction in preterm ...
Pediatric experts from Le Bonheur’s Heart Institute and the University of Tennessee Health Science Center will present lectures, posters, abstracts and hands-on workshops. Pediatric experts from Le ...
Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.
The cyclooxygenase inhibitor ibuprofen may be used to treat patent ductus arteriosus (PDA) in preterm infants. Whether selective early treatment of large PDAs with ibuprofen would improve short-term ...
“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...
An FDA alert warned of problems with some Mobile Power Units of the HeartMate II and HeartMate 3 left ventricular assist devices. Medtronic's thin OmniaSecure defibrillation lead got FDA approval for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback